索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]高鑫宇,彭瑜,张钲.Fetuin-A在冠状动脉粥样硬化性心脏病中的作用[J].国际心血管病杂志,2017,05:289-291298.
点击复制

Fetuin-A在冠状动脉粥样硬化性心脏病中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2017年05期
页码:
289-291298
栏目:
综述
出版日期:
2017-10-20

文章信息/Info

Title:
-
作者:
高鑫宇; 彭瑜; 张钲
730000 兰州大学第一医院心血管内科,甘肃省心脏临床医学中心,甘肃省心血管疾病重点实验室
Author(s):
-
关键词:
Fetuin-A;  血管钙化;  冠状动脉粥样硬化性心脏病;  胰岛素抵抗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2017.05.010
文献标识码:
-
摘要:
Fetuin-A是一种具有多种功能的血浆糖蛋白,参与调节钙磷代谢、异位钙磷沉积和骨重建。研究发现,Fetuin -A在心血管系统中也有重要的作用,可抑制冠状动脉钙化、促进冠状动脉粥样硬化发展和预测冠状动脉粥样硬化性心脏 病(冠心病)的严重程度及预后。
Abstract:
-

参考文献/References

[1] Mattinzoli D, Rastaldi MP, Ikehata M, et al. FGF23-regulated production of fetuin-A(AHSG)in osteocytes[J]. Bone, 2016, 83(1):35-47.
[2] Holt SG, Smith ER. Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease[J]. Nephrol Dial Transplant, 2016, 31(10):1583-1587.
[3] Mathews ST, Ren G, He X, et al. Ser312-phosphorylated fetuin-A: role in insulin action and insulin resistance[J]. Diabetologia, 2014, 57(1):S97-S97.
[4] Dabrowska AM, Tarach JS, Wojtysiak-Duma B, et al. Fetuin-A(AHSG)and its usefulness in clinical practice[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015, 159(3):352-359.
[5] Chen HY, Chiu YL, Hsu SP, et al. Relationship between fetuin A, vascular calcification and fracture risk in dialysis patients[J]. PLoS One, 2016, 11(7):e0158789.
[6] Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein[J]. Recent Pat Endocr Metab Immune Drug Discov, 2011, 5(2):124-146.
[7] Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system[J]. Adv Clin Chem, 2012, 56:175- 195.
[8] Herrmann M, Kinkeldey A, Jahnen-Dechent W. Fetuin-A function in systemic mineral metabolism[J]. Trends Cardiovasc Med, 2012, 22(8):197-201.
[9] Sharqawy MM, Seif KA, Azim A, et al. Vascular and valvular calcification in dialysis patients: the role of fetuin-A[J]. IJRSR, 2012, 6(10):7084-7088.
[10] Baum C, Garlichs CD, Achenbach S, et al. The role of fetuin-A for the development and progress of coronary artery calcification in a 12-months follow-up[J]. Handmade Museum, 2012, 50(10):856-862.
[11] Fisher E, Stefan N, Saar K, et al. Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study[J]. Circ Cardiovasc Genet, 2009, 2(6):607- 613.
[12] Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke[J]. Circulation, 2008, 118(24):2555-2562.
[13] Zhao ZW, Lin CG, Wu LZ, et al. Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes[J]. Biomarkers, 2013, 18(2):160-164.
[14] Dogru T, Genc H, Tapan S, et al. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease[J]. Clin Endocrinol(Oxf), 2013, 78(5):712-717.
[15] Goustin AS, Abou-Samra AB. The "thrifty" gene encoding Ahsg/Fetuin-A meets the insulin receptor: insights into the mechanism of insulin resistance[J]. Cell Signal, 2011, 23(6):980-990.
[16] Singh M, Sharma PK, Garg VK, et al. Role of fetuin-A in atherosclerosis associated with diabetic patients[J]. J Pharm Pharmacol, 2012, 64(12):1703-1708.
[17] Shim YS, Kang MJ, Oh YJ, et al. Fetuin-A as an alternative marker for insulin resistance and cardiovascular risk in prepubertal children[J]. J Atheroscler Thromb, 2017, 86(1):1-8.
[18] Hizli �瘙 塁 , Abaci A, Özdemir O, et al. Relation of fetuin A levels with cardiac, subcutaneous lipid accumulation and insulin resistance parameters in Turkish obese children[J]. J Pediatr Endocrinol Metab, 2016, 29(6):669-673.
[19] Liu H, Jiang D. Fractalkine/CX3CR1 and atherosclerosis[J]. Clin Chim Acta, 2011, 412(13/14):1180- 1186.
[20] Fadini GP, Ciciliot S. Vascular smooth muscle cells and monocyte-macrophages accomplice in the accelerated atherosclerosis of insulin resistance states[J]. Cardiovasc Res, 2014, 103(2):194-195.
[21] Naito C, Hashimoto M, Watanabe K, et al. Facilitatory effects of fetuin-A on atherosclerosis[J]. Atherosclerosis, 2016, 246(13):344-351.
[22] Wang H, Sama AE. Anti-inflammatory role of fetuin-A in injury and infection[J]. Curr Mol Med, 2012, 12(5):625-633.
[23] Akin F, Celik O, Altun I, et al. Relationship of fibroblast growth factor 23 and fetuin-A to coronary atherosclerosis[J]. J Diabetes Complications, 2015, 29(4):550-555.
[24] Mori K, Ikari Y, Jono S, et al. Fetuin-A is associated with calcified coronary artery disease[J]. Coron Artery Dis, 2010, 21(5):281-285.
[25] Zissimopoulos A, Baloka L, Nagorni E, et al. Serum levels of fetuin-A in patients with coronary artery disease. Corellation with SPET myocardium scintigraphy[J]. Hell J Nucl Med, 2015, 18(Suppl 1):147.
[26] Lim P, Danchin N, Simon T, et al. Inflammatory imbalance assessed by fetuin-A and CRP level is a srong predictor of outcome in acute coronary syndromes(from fast-MI registry)[J]. Arch Cardiovasc Dis, 2011, 3(1):4-5.
[27] Feistritzer HJ, Klug G, Reinstadler SJ, et al. Fetuin-A is related to infarct size, left ventricular function and remodelling after acute STEMI[J]. Open heart, 2015, 2(1):e000244.
[28] Lim P, Collet JP, Moutereau S, et al. Fetuin-A is an independent predictor of death after ST- elevation myocardial infarction[J]. Clin Chem, 2007, 53(10):1835-1840.
[29] Lim P, Moutereau S, Simon T, et al. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes(from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI])[J]. Am J Cardiol, 2013, 111(1):31-37.

备注/Memo

备注/Memo:
通信作者:张钲,Email:zhangccu@163.com
更新日期/Last Update: 2017-10-20